Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Stellanova Therapeutics is developing the first cancer therapies targeting cancer-associated fibroblasts (CAFs) and their symbiotic interactions within the tumor microenvironment. The company was founded based on research out of Dr. Rosa Hwang’s lab at MD Anderson Cancer Center demonstrating that targeting factors produced by stellate cells, a star-shaped subtype of CAFs present in pancreatic cancer, which have the potential...
Stellanova Therapeutics is developing the first cancer therapies targeting cancer-associated fibroblasts (CAFs) and their symbiotic interactions within the tumor microenvironment. The company was founded based on research out of Dr. Rosa Hwang’s lab at MD Anderson Cancer Center demonstrating that targeting factors produced by stellate cells, a star-shaped subtype of CAFs present in pancreatic cancer, which have the potential to both directly combat cancer and make tumor cells more vulnerable to traditional therapeutic approaches, including chemotherapy and immunotherapy.

List your booth number for exhibitions, ask us